Longeveron (NASDAQ:LGVN) Announces Quarterly Earnings Results, Beats Expectations By $1.56 EPS

Longeveron (NASDAQ:LGVN) released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($1.75) by $1.56, Zacks reports. Longeveron had a negative net margin of 1,977.59% and a negative return on equity of 223.19%. The business had revenue of $0.29 million during the quarter, compared to analyst estimates of $0.33 million.

Here are the key takeaways from Longeveron’s conference call:

• ELPIS II topline results for laromestrocel in hypoplastic left heart syndrome are expected in September, with database lock planned for August 31. Management believes favorable results could support a BLA pathway, potentially including priority review.
• Longeveron ended the quarter with $10.1 million in cash and expects existing funds to support operations only through the fourth quarter of 2026. Net loss rose 22% year over year to $6.1 million, while revenue declined 10% to $0.3 million.
• Management said it has made progress on manufacturing and CMC preparations and is exploring partnerships with major pharmaceutical companies, particularly if the HLHS data are positive. A partner could provide additional capital, commercial infrastructure, and global reach.
• Laromestrocel was selected as a finalist in the XPRIZE Healthspan competition from more than 600 applicants and received a $1 million award, adding external validation to the age-related frailty program and potentially supporting future longevity partnerships.
• The company is preparing a potential 2027 Phase II trial in pediatric dilated cardiomyopathy, supported by an already-effective IND and possible eligibility for a priority review voucher, but the program remains preclinical-to-early clinical planning and requires further funding.

Longeveron Stock Down 3.8%

Longeveron stock traded down $0.10 during mid-day trading on Wednesday, hitting $2.62. The company had a trading volume of 53,880 shares, compared to its average volume of 229,913. The stock has a market cap of $8.34 million, a price-to-earnings ratio of -0.26 and a beta of -0.25. Longeveron has a 1 year low of $2.30 and a 1 year high of $12.30. The business has a fifty day moving average of $6.60 and a 200 day moving average of $7.81.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Wall Street Zen lowered Longeveron from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings downgraded Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Longeveron currently has a consensus rating of “Hold” and an average target price of $80.00.

About Longeveron

Longeveron Inc (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines intended to address serious and life-threatening conditions. Its lead product candidate, Lomecel-B, is an allogeneic medicinal signaling cell therapy derived from the bone marrow of healthy adult donors. The company is investigating the therapy for its potential to promote tissue repair, modulate inflammation and support blood-vessel formation.

Lomecel-B is being evaluated in clinical programs targeting hypoplastic left heart syndrome, an uncommon and severe congenital heart condition, as well as aging-related frailty and Alzheimer’s disease.